硅谷资本圈新生意：5万美元，定制一个“完美”婴儿

Core Insights - The article discusses the emerging trend of using Preimplantation Genetic Testing for Polygenic Disorders (PGT-P) to select embryos based on desirable traits such as intelligence, health, and appearance, leading to a potential genetic class divide in society [1][2][15]. Industry Overview - PGT-P technology allows couples to provide multiple embryos for genetic decoding and scoring, predicting the likelihood of various traits in their future children [2][3]. - The technology has gained attention from high-profile individuals, including Elon Musk, who reportedly used PGT-P services for at least one of his children [5]. Company Dynamics - Several companies are involved in the PGT-P space, including Orchid, Genomic Prediction, and Nucleus Genomics, with significant funding from investors like Peter Thiel [5][11]. - Orchid has raised approximately $20 million, Genomic Prediction around $36 million, and Nucleus Genomics completed a $60 million Series A funding round [5]. Market Challenges - Despite the initial enthusiasm and funding, the industry faces significant challenges related to ethical concerns and regulatory scrutiny, leading to hesitance among investors [6][11]. - Genomic Prediction's attempts to raise additional funds were halted due to perceived policy risks, highlighting the precarious nature of the PGT-P market [11]. Ethical and Scientific Concerns - The scientific community has raised alarms about the lack of rigorous clinical validation for PGT-P technology, with warnings from organizations like the European Society of Human Genetics [12][14]. - Critics argue that the technology may reinforce social inequalities by creating a "genetic class" where wealth determines access to genetic enhancements [15][16]. Consumer Perspective - Despite the controversies, there remains a market demand for PGT-P services, as evidenced by individuals like Rafal, who pursued embryo selection to ensure desirable traits for his child [18].